The mission of the Georgetown Lombardi Comprehensive Cancer Center (LCCC) is to prevent, treat and cure cancers by linking scientific discovery, expert and compassionate patient care, quality education, and partnership with the community, guided by the principle of cura personalis ("care for the whole person"). LCCC is led by Director Louis M. Weiner, MD, a medical oncologist and immunotherapy expert, with the support of Deputy Director Michael B. Atkins, MD, six Associate Directors (ADs) and Sandra M. Swain, LCCC's clinical network representative. Four Research Programs-Breast Cancer, Cancer Prevention and Control, Experimental Therapeutics and Molecular Oncology-conduct high-impact studies supported by nine Shared Resources. LCCC has 91 members, with a current annual total of $28.7M in peer-reviewed ($18.5M NCI) cancer-focused funding (direct costs), resulting in 1,100 peer-reviewed cancer-related publications from 2009-2012;32% of which involved intra- and/or interprogrammatic collaborations, and 53% of which involved external collaborations. In 2012, LCCC placed 244 patients on interventional clinical trials (13% of new patients). Notable accomplishments include: 1) discovery of a transformative methodology for epithelial cell reprogramming with rapid translation into clinical trials;2) development of enabling tools such as novel computational modeling for drug repurposing and integrated informatic platforms;3) basic discovery (novel mechanisms for genomic instability;transcriptional targeting in Ewing sarcoma;resistance determinants in the EGFR network);4) leadership of high-impact clinical trials (e.g., evaluation of pertuzumab in breast cancer, role of bendamustine in follicular lymphoma);5) national collaborative modeling research informing screening mammography guidelines and 6) operational enhancements that include creation of the MedStar Georgetown Cancer Network to expand clinical research in LCCC's catchment area under the direction of recent recruit, Giuseppe Giaccone, MD, PhD (AD, Clinical Research);a reorganization of clinical trial management and regulatory activities to better support the Network;and the continued development of community outreach and research sites in the poorest wards of the District of Columbia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA051008-21
Application #
8661994
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-08-15
Project End
2019-04-30
Budget Start
2014-09-09
Budget End
2015-04-30
Support Year
21
Fiscal Year
2014
Total Cost
$2,250,000
Indirect Cost
$795,486
Name
Georgetown University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Bae, Woo Kyun; Yoo, Kyung Hyun; Lee, Ji Shin et al. (2015) The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers. Mol Carcinog 54:1172-80
Adams, Inez; Christopher, Juleen; Williams, Karen Patricia et al. (2015) What Black Women Know and Want to Know About Counseling and Testing for BRCA1/2. J Cancer Educ 30:344-52
Butrick, Morgan; Kelly, Scott; Peshkin, Beth N et al. (2015) Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling. Genet Med 17:467-75
London, Laricca; Hurtado-de-Mendoza, Alejandra; Song, Minna et al. (2015) Motivators and barriers to Latinas' participation in clinical trials: the role of contextual factors. Contemp Clin Trials 40:74-80
Mays, Darren; Niaura, Raymond S; Evans, W Douglas et al. (2015) Cigarette packaging and health warnings: the impact of plain packaging and message framing on young smokers. Tob Control 24:e87-92
Zhi, Xiuling; Lin, Ling; Yang, Shaoxian et al. (2015) ?II-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin. Hepatology 61:598-612
Rush, Christina L; Darling, Margaret; Elliott, Maria Gloria et al. (2015) Engaging Latina cancer survivors, their caregivers, and community partners in a randomized controlled trial: Nueva Vida intervention. Qual Life Res 24:1107-18
Heckler, Mary Mazzotta; Riggins, Rebecca B (2015) ERR? splice variants differentially regulate cell cycle progression. Cell Cycle 14:31-45
Kim, B; Wang, S; Lee, J M et al. (2015) Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene 34:1083-93
Tong, Angie; Kelly, Scott; Nusbaum, Rachel et al. (2015) Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. Psychooncology 24:33-9

Showing the most recent 10 out of 544 publications